Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Post-Market Trading 05-20 17:35:42 EDT

150.24

+0.84

+0.56%

盘后150.24

+0.000.00%

16:16 EDT

High150.78	Low147.78	Vol368.45K
Open149.30	D1 Closing149.40	Amplitude2.01%
Mkt Cap19.00B	Tradable Cap18.92B	Total Shares126.49M
T/O55.08M	T/O Rate0.29%	Tradable Shares125.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":150.24,"timestamp":1716235200000,"preClose":149.4,"halted":0,"volume":368454,"hourTrading":{"tag":"盘后","latestPrice":150.24,"preClose":150.24,"latestTime":"16:16 EDT","volume":7725,"amount":1160604,"timestamp":1716236213628},"delay":0,"floatShares":125958147,"shares":126491778,"eps":-2.647864,"marketStatus":"Post-Market Trading","change":0.84,"latestTime":"05-20 17:35:42 EDT","open":149.3,"high":150.78,"low":147.78,"amount":55084412.0755,"amplitude":0.02008,"askPrice":152,"askSize":2,"bidPrice":148.38,"bidSize":58,"shortable":3,"etf":0,"ttmEps":-2.647864,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1716249600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":149.4,"preHourTrading":{"tag":"盘前","latestPrice":149.01,"preClose":149.4,"latestTime":"09:29 EDT","volume":124,"amount":18500.999639999998,"timestamp":1716211799999},"postHourTrading":{"tag":"盘后","latestPrice":150.24,"preClose":150.24,"latestTime":"16:16 EDT","volume":7725,"amount":1160604,"timestamp":1716236213628},"volumeRatio":0.600086},"requestUrl":"/m/hq/s/ALNY/","defaultTab":"news","newsList":[{"id":"2436189468","title":"Roche Is Joining The Obesity Party But Questions Remain","url":"https://stock-news.laohu8.com/highlight/detail?id=2436189468","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436189468?lang=en_us&edition=fundamental","pubTime":"2024-05-18 23:18","pubTimestamp":1716045533,"startTime":"0","endTime":"0","summary":"Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24.The full data presentation is needed to assess safety and tolerabili","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767278670/image_1767278670.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694321-roche-is-joining-the-obesity-party-but-questions-remain","is_publish_highlight":false,"gpt_icon":0},{"id":"2436415219","title":"Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2436415219","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436415219?lang=en_us&edition=fundamental","pubTime":"2024-05-17 22:44","pubTimestamp":1715957045,"startTime":"0","endTime":"0","summary":"The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments.Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally bec","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211364640/image_1211364640.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1211364640/image_1211364640.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694100-arrowhead-pharmaceuticals-focus-turns-to-upcoming-pipeline-inflection-point","is_publish_highlight":false,"gpt_icon":0},{"id":"2435597216","title":"Most attractive short-term overwriting stocks for June expiration - Goldman","url":"https://stock-news.laohu8.com/highlight/detail?id=2435597216","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435597216?lang=en_us&edition=fundamental","pubTime":"2024-05-15 22:43","pubTimestamp":1715784216,"startTime":"0","endTime":"0","summary":"Goldman Sachs analysts identified short-term overwriting opportunities in large-cap, high implied volatility stocks that do not have earnings events. Analysts said that event timing and stock characte","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1718650567/image_1718650567.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1718650567/image_1718650567.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4106606-most-attractive-short-term-overwriting-stocks-for-june-expiration-goldman","is_publish_highlight":false,"gpt_icon":0},{"id":"2435687639","title":"S&P 500 Futures Steady In Premarket Trading; Monday.Com, Nextracker Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2435687639","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435687639?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:31","pubTimestamp":1715772660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, monday.com Ltd.  was up 19.4% in pre-market trading, and Nextracker Inc.  was up 13.9%.Alnylam Pharmaceuticals Inc. , Shift4 Payments Inc. , and Nu Holdings Ltd. Cl A  were all posting gains of at least 4%. In early trading, Neurocrine Biosciences Inc.  and Medpace Holdings Inc.  had posted declines, falling 4.7% and 4.0%, respectively.Meanwhile S&P 500 futures were up 0.04%, with futures for the Dow Jones Industrial Average rising 0.02%. The Cboe Volatility Index futures were down 1.38%.In commodities news, Brent crude oil futures were down 0.57%, while gold futures were up 0.51%. Bitcoin climbed 1.43% to $62,435.In afternoon trading, stocks in Europe are up, with the STOXX Europe 600 Index rising 0.31% and the FTSE 100 Index climbing 0.32% from the previous close.U.S. stock markets open for trading at 9:30 a.m. ET.Data source: Dow Jones Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434531323","title":"Cantor picks 14 undervalued biotech stocks worth a second look","url":"https://stock-news.laohu8.com/highlight/detail?id=2434531323","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434531323?lang=en_us&edition=fundamental","pubTime":"2024-05-12 23:00","pubTimestamp":1715526000,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards as significantly undervalued and worth a \"fresh\" look.  All of the picks were down more than 20% year-to-date, as of ","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482562791/image_1482562791.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482562791/image_1482562791.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104913-cantor-picks-14-undervalued-biotech-stocks-worth-a-second-look","is_publish_highlight":false,"gpt_icon":0},{"id":"2434818807","title":"Alnylam Pharmaceuticals Outperformed in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2434818807","media":"Motley Fool","top":-1,"share":"https://ttm.financial/m/news/2434818807?lang=en_us&edition=fundamental","pubTime":"2024-05-11 06:51","pubTimestamp":1715381460,"startTime":"0","endTime":"0","summary":"The rare disease specialist beat Wall Street's expectations with strong revenue growth and smaller-than-anticipated losses.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F775794%2Flab-pharma-microscope.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F775794%2Flab-pharma-microscope.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/data-news/2024/05/10/alnylam-pharmaceuticals-outperformed-in-q1/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434302542","title":"Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2434302542","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434302542?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:20","pubTimestamp":1715289600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Incyte Corp.  slipped 0.02% to $53.50 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.51% to 5,214.08 and the Dow Jones Industrial Average  rising 0.85% to 39,387.76.This was the stock's second consecutive day of losses.Incyte Corp. closed $13.87 below its 52-week high , which the company reached on January 4th.Despite its losses, the stock outperformed some of its competitors Thursday, as Alnylam Pharmaceuticals Inc.  fell 0.60% to $151.37.Trading volume  remained 496,993 below its 50-day average volume of 1.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled May 9, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433207120","title":"Alnylam Issues 2023 Corporate Responsibility Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2433207120","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433207120?lang=en_us&edition=fundamental","pubTime":"2024-05-07 20:00","pubTimestamp":1715083200,"startTime":"0","endTime":"0","summary":"– Highlighted New Disclosures of Company’s Impact on the Environment—Including Multiyear Data on Greenhouse Gas  Emissions, Energy, Water, and Waste Management Footprint–。– Expanded Alnylam Challengers Global Health Equity Initiative –。CAMBRIDGE, Mass., May 07, 2024----Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition expands data disclosures across each pillar and highlights examples of the company’s commitment to ensuring patient access, reducing health inequities, and being a responsible steward of the environment.\"As we grow and progress in our quest to realize the promise of RNAi, we continue to expand our leadership and impact as a responsible corporate citizen. I am proud of the broad range of initiatives highlighted in this report, which reflect our efforts to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/h6NS_I.5OQgR9gCdI4Ed6A--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/79090eca98eff0c05b9df01449f81dab","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/h6NS_I.5OQgR9gCdI4Ed6A--~B/aD00NDA7dz0xNTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/79090eca98eff0c05b9df01449f81dab"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-issues-2023-corporate-responsibility-120000181.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433340274","title":"Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2433340274","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433340274?lang=en_us&edition=fundamental","pubTime":"2024-05-07 19:14","pubTimestamp":1715080440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2024 07:14 ET (11:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432184576","title":"Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2432184576","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432184576?lang=en_us&edition=fundamental","pubTime":"2024-05-04 00:29","pubTimestamp":1714753740,"startTime":"0","endTime":"0","summary":"The adjusted figure excluded items like stock-based compensation expenses and realized and unrealized  loss on marketable equity securities.Alnylam recorded total revenues of $494 million in the quarter, which surpassed the Zacks Consensus Estimate of $421 million. In the year-ago quarter, total revenues were $319 million. Net product revenues were $365 million, up 32% year over year on a reported basis, as well as at constant exchange rate, driven by increased patient numbers for Givlaari , Oxlumo  and the newly approved Amvuttra .Net revenues from collaborators were $119 million, up 225% from $36 million reported in the year-ago quarter. The uptick was primarily driven by revenues recognized under the company’s licensing agreement with Roche RHHBY, which included a $65 million milestone payment that Alnylam received upon dosing the first patient in the zilebesiran KARDIA-3 clinical study for hypertension indication.Year to date, shares of Alnylam have plunged 21.5% compared with thei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-alny-q1-loss-narrower-162900353.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432037699","title":"Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2432037699","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432037699?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:21","pubTimestamp":1714742509,"startTime":"0","endTime":"0","summary":"NasdaqGS:ALNY Earnings and Revenue Growth May 3rd 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 14%. Earnings per share  also surpassed analyst estimates by 55%.Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 4.6% from a week ago.You should learn about the   2 warning signs  we've spotted with Alnylam Pharmaceuticals .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-first-quarter-2024-132149217.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432421946","title":"Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2432421946","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432421946?lang=en_us&edition=fundamental","pubTime":"2024-05-03 15:11","pubTimestamp":1714720315,"startTime":"0","endTime":"0","summary":"Total Product Revenues: $365 million, 32% growth year-over-year.TTR Franchise Revenue: $264 million, 29% growth year-over-year.Rare Franchise Revenue: $101 million, 40% growth year-over-year.Net Revenue from Collaborations: $119 million, 225% increase year-over-year.Gross Margin on Product Sales: Consistent at 85%.Non-GAAP Operating Gain: $2 million, significant improvement from Q1 2023.Cash, Cash Equivalents, and Marketable Securities: $2.4 billion, stable from end of 2023.2024 Revenue Guidance: Anticipated combined net product revenues between $1.4 billion and $1.5 billion.2024 Collaboration and Royalty Revenue Guidance: Range of $325 million to $425 million.2024 Combined Non-GAAP R&D and SG&A Expenses Guidance: Between $1.675 billion and $1.775 billion.GuruFocus has detected 3 Warning Signs with ALNY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Alnylam Pharmaceuticals Inc  reported a robust 32% year-over-year growth in product r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-inc-alny-q1-071155965.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432929912","title":"Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight","url":"https://stock-news.laohu8.com/highlight/detail?id=2432929912","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432929912?lang=en_us&edition=fundamental","pubTime":"2024-05-03 13:06","pubTimestamp":1714712783,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals Inc  showcases robust revenue growth with a 54.8% increase in total revenues year-over-year.Despite increased revenues, ALNY faces a net loss, highlighting the need for strategic financial management.ALNY's commitment to RNAi therapeutics innovation positions it for potential market expansion and competitive advantage.Market dynamics and competitive pressures present both opportunities and threats to ALNY's growth trajectory.Alnylam Pharmaceuticals Inc , a pioneer in RNA interference  therapeutics, filed its 10-Q on May 2, 2024, revealing a detailed financial and operational overview. The company reported a significant increase in total revenues, climbing to $494.3 million in the first quarter of 2024 from $319.3 million in the same period the previous year, marking a 54.8% increase. This growth was driven by a substantial rise in net product revenues, which soared from $276.3 million to $365.2 million, and a more than threefold increase in net revenues from col","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NsHL7Tz9AQ_9SwprJATphw--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/e7a9470355b3c84cf793ac43316b60c8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NsHL7Tz9AQ_9SwprJATphw--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/e7a9470355b3c84cf793ac43316b60c8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/decoding-alnylam-pharmaceuticals-inc-alny-050623562.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432133319","title":"Strong Financial Growth and Promising Clinical Trials Bolster Buy Rating for Alnylam Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2432133319","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432133319?lang=en_us&edition=fundamental","pubTime":"2024-05-03 11:45","pubTimestamp":1714707923,"startTime":"0","endTime":"0","summary":"Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Keay Nakae from C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-financial-growth-and-promising-clinical-trials-bolster-buy-rating-for-alnylam-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-financial-growth-and-promising-clinical-trials-bolster-buy-rating-for-alnylam-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432934698","title":"Alnylam Pharmaceuticals Price Target Maintained With a $200.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2432934698","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432934698?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:51","pubTimestamp":1714675860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 02, 2024 14:51 ET (18:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432413935","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2432413935","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432413935?lang=en_us&edition=fundamental","pubTime":"2024-05-03 01:40","pubTimestamp":1714671623,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report) and Zimmer Biomet Holding...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-zimmer-biomet-holdings-zbh?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-zimmer-biomet-holdings-zbh?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432989238","title":"Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432989238","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432989238?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:36","pubTimestamp":1714664168,"startTime":"0","endTime":"0","summary":"The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2024 Q1 earnings call.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688528-alnylam-pharmaceuticals-inc-2024-q1-results-earnings-call-presentation","is_publish_highlight":false,"gpt_icon":0},{"id":"2432989474","title":"Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics","url":"https://stock-news.laohu8.com/highlight/detail?id=2432989474","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432989474?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:00","pubTimestamp":1714658415,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 for the same period compares to -$1.40 a year ago.The reported revenue represents a surprise of +17.39% over the Zacks Consensus Estimate of $421.1 million. With the consensus EPS estimate being -$0.75, the EPS surprise was +78.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/compared-estimates-alnylam-alny-q1-140015629.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432094096","title":"Alnylam Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2432094096","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432094096?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:33","pubTimestamp":1714656788,"startTime":"0","endTime":"0","summary":"* Alnylam Pharmaceuticals Inc    reported a quarterly adjusted loss of 52 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432598338","title":"Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2432598338","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432598338?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:10","pubTimestamp":1714655404,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 78.67%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.20 per share when it actually produced a loss of $1.10, delivering a surprise of 8.33%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Alnylam , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $494.33 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 17.39%. This compares to year-ago revenues of $319.29 million. The company has topped consensus revenue estimates two times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can ha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-reports-q1-131004447.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.0281},{"period":"3month","weight":0.0163},{"period":"6month","weight":-0.0875},{"period":"1year","weight":-0.2131},{"period":"ytd","weight":-0.2195}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.031314},{"month":2,"riseRate":0.5,"avgChangeRate":0.008316},{"month":3,"riseRate":0.45,"avgChangeRate":-0.018527},{"month":4,"riseRate":0.4,"avgChangeRate":-0.019432},{"month":5,"riseRate":0.6,"avgChangeRate":0.03579},{"month":6,"riseRate":0.6,"avgChangeRate":0.035552},{"month":7,"riseRate":0.7,"avgChangeRate":0.108614},{"month":8,"riseRate":0.55,"avgChangeRate":0.028475},{"month":9,"riseRate":0.5,"avgChangeRate":0.034438},{"month":10,"riseRate":0.4,"avgChangeRate":-0.044685},{"month":11,"riseRate":0.8,"avgChangeRate":0.089497},{"month":12,"riseRate":0.5,"avgChangeRate":0.016329}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction